Pub Date : 2024-12-27DOI: 10.1016/j.hoc.2024.11.002
Ayesha Hashmi, Lilli J Greiner, Pradeep S Chauhan, Jeffrey J Szymanski, Sean Park, Kenneth Olivier, Dawn Owen, Aadel A Chaudhuri
Circulating tumor DNA (ctDNA) is emerging as a transformative biomarker in the management of non-small cell lung cancer (NSCLC). This review focuses on its role in detecting minimal residual disease (MRD), predicting treatment response, and guiding therapeutic decision-making in radiation oncology and immunotherapy. Key studies demonstrate ctDNA's prognostic value, particularly in identifying relapse risk and refining patient stratification for curative-intent and consolidative treatments. Future research is essential to standardize ctDNA assays, optimize integration into clinical workflows, and expand its clinical utility. This biomarker holds substantial promise by enabling non-invasive, real-time monitoring and improving outcomes for patients with NSCLC and beyond.
{"title":"Emergence of Circulating Tumor DNA as a Precision Biomarker in Lung Cancer Radiation Oncology and Beyond.","authors":"Ayesha Hashmi, Lilli J Greiner, Pradeep S Chauhan, Jeffrey J Szymanski, Sean Park, Kenneth Olivier, Dawn Owen, Aadel A Chaudhuri","doi":"10.1016/j.hoc.2024.11.002","DOIUrl":"https://doi.org/10.1016/j.hoc.2024.11.002","url":null,"abstract":"<p><p>Circulating tumor DNA (ctDNA) is emerging as a transformative biomarker in the management of non-small cell lung cancer (NSCLC). This review focuses on its role in detecting minimal residual disease (MRD), predicting treatment response, and guiding therapeutic decision-making in radiation oncology and immunotherapy. Key studies demonstrate ctDNA's prognostic value, particularly in identifying relapse risk and refining patient stratification for curative-intent and consolidative treatments. Future research is essential to standardize ctDNA assays, optimize integration into clinical workflows, and expand its clinical utility. This biomarker holds substantial promise by enabling non-invasive, real-time monitoring and improving outcomes for patients with NSCLC and beyond.</p>","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-17DOI: 10.1016/j.hoc.2024.11.003
Jessica Scarborough, Davis Weaver, Jacob Scott
Gene expression signatures (GES) are a powerful tool in oncology used for classification, prognostication, and therapeutic response prediction of malignancies. In this article, we review the disease site guidelines by the National Comprehensive Cancer Network that use GES for treatment planning and clinical use. We identified 4 cancer types for which treatment decisions are frequently influenced by GES. Future developments in the field of GES are likely to include expanded data sources to personalize radiation therapy dosing and predict response to immunotherapy. Ongoing challenges in GES may be addressed to ensure that all patients with cancer benefit from precision oncology.
{"title":"Gene Signatures and Oncology Treatment Implications.","authors":"Jessica Scarborough, Davis Weaver, Jacob Scott","doi":"10.1016/j.hoc.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.hoc.2024.11.003","url":null,"abstract":"<p><p>Gene expression signatures (GES) are a powerful tool in oncology used for classification, prognostication, and therapeutic response prediction of malignancies. In this article, we review the disease site guidelines by the National Comprehensive Cancer Network that use GES for treatment planning and clinical use. We identified 4 cancer types for which treatment decisions are frequently influenced by GES. Future developments in the field of GES are likely to include expanded data sources to personalize radiation therapy dosing and predict response to immunotherapy. Ongoing challenges in GES may be addressed to ensure that all patients with cancer benefit from precision oncology.</p>","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-17DOI: 10.1016/j.hoc.2024.11.007
Xiaoying Liang, Homan Mohammadi, Kathryn C Moreno, Chris J Beltran, Adam L Holtzman
Heavy ion radiotherapy is an emerging technology for treating radioresistant solid tumors. Unlike current low-linear energy transfer techniques, heavy ion radiotherapy, such as carbon ion radiotherapy, enhances the biologic effects related to cancer therapy. Prospective clinical evidence has demonstrated feasibility and efficacy in several disease sites, including head and neck, thoracic, central nervous system, gastrointestinal, pelvic tumors, and sarcomas. Although presently unavailable in the Americas, Mayo Clinic is constructing a heavy ion facility in the United States that is planned for clinical operation in 2028.
{"title":"Heavy Ion Particle Therapy in Modern Day Radiation Oncology.","authors":"Xiaoying Liang, Homan Mohammadi, Kathryn C Moreno, Chris J Beltran, Adam L Holtzman","doi":"10.1016/j.hoc.2024.11.007","DOIUrl":"https://doi.org/10.1016/j.hoc.2024.11.007","url":null,"abstract":"<p><p>Heavy ion radiotherapy is an emerging technology for treating radioresistant solid tumors. Unlike current low-linear energy transfer techniques, heavy ion radiotherapy, such as carbon ion radiotherapy, enhances the biologic effects related to cancer therapy. Prospective clinical evidence has demonstrated feasibility and efficacy in several disease sites, including head and neck, thoracic, central nervous system, gastrointestinal, pelvic tumors, and sarcomas. Although presently unavailable in the Americas, Mayo Clinic is constructing a heavy ion facility in the United States that is planned for clinical operation in 2028.</p>","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-17DOI: 10.1016/j.hoc.2024.11.005
Erin McCammack, Sara Alcorn
Patient-reported outcomes (PROs) assessments arguably provide the most accurate description of the patient experience, as they are directly derived from the patient without the filter of a provider. Utilizing instruments to assess PROs in radiation oncology enables a provider to measure pretreatment, on-treatment, and posttreatment symptoms. In the clinic, PROs are supplemental to physician-derived ratings that help create a complete clinical picture of a patient at a given time point to inform shared decision-making. A compilation of PROs that arise within trials, specific for given treatment regimes, will be invaluable for patients faced with choosing between options.
{"title":"Patient-Reported Outcomes in Radiation Oncology.","authors":"Erin McCammack, Sara Alcorn","doi":"10.1016/j.hoc.2024.11.005","DOIUrl":"https://doi.org/10.1016/j.hoc.2024.11.005","url":null,"abstract":"<p><p>Patient-reported outcomes (PROs) assessments arguably provide the most accurate description of the patient experience, as they are directly derived from the patient without the filter of a provider. Utilizing instruments to assess PROs in radiation oncology enables a provider to measure pretreatment, on-treatment, and posttreatment symptoms. In the clinic, PROs are supplemental to physician-derived ratings that help create a complete clinical picture of a patient at a given time point to inform shared decision-making. A compilation of PROs that arise within trials, specific for given treatment regimes, will be invaluable for patients faced with choosing between options.</p>","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-05DOI: 10.1016/j.hoc.2024.09.002
Michael D’Angelica MD, FACS
{"title":"Metastatic Liver Tumors: The Path to Disease-Free Survival","authors":"Michael D’Angelica MD, FACS","doi":"10.1016/j.hoc.2024.09.002","DOIUrl":"10.1016/j.hoc.2024.09.002","url":null,"abstract":"","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":"39 1","pages":"Pages xiii-xiv"},"PeriodicalIF":2.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-05DOI: 10.1016/S0889-8588(24)00132-1
Michael D’Angelica (Editor)
{"title":"Management of Metastatic Liver Tumors","authors":"Michael D’Angelica (Editor)","doi":"10.1016/S0889-8588(24)00132-1","DOIUrl":"10.1016/S0889-8588(24)00132-1","url":null,"abstract":"","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":"39 1","pages":"Page i"},"PeriodicalIF":2.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-05DOI: 10.1016/j.hoc.2024.08.007
H. Richard Alexander Jr. MD , Virginia Devi-Chou BA, MA
{"title":"Hepatic Perfusion for Diffuse Metastatic Cancer to the Liver","authors":"H. Richard Alexander Jr. MD , Virginia Devi-Chou BA, MA","doi":"10.1016/j.hoc.2024.08.007","DOIUrl":"10.1016/j.hoc.2024.08.007","url":null,"abstract":"","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":"39 1","pages":"Pages 177-190"},"PeriodicalIF":2.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-05DOI: 10.1016/S0889-8588(24)00134-5
{"title":"Contributors","authors":"","doi":"10.1016/S0889-8588(24)00134-5","DOIUrl":"10.1016/S0889-8588(24)00134-5","url":null,"abstract":"","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":"39 1","pages":"Pages iii-vi"},"PeriodicalIF":2.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-05DOI: 10.1016/j.hoc.2024.08.011
Chandrasekhar Padmanabhan MD , Daniel P. Nussbaum MD , Michael D’Angelica MD
{"title":"Surgical Management of Colorectal Cancer Liver Metastases","authors":"Chandrasekhar Padmanabhan MD , Daniel P. Nussbaum MD , Michael D’Angelica MD","doi":"10.1016/j.hoc.2024.08.011","DOIUrl":"10.1016/j.hoc.2024.08.011","url":null,"abstract":"","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":"39 1","pages":"Pages 1-24"},"PeriodicalIF":2.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号